Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Microbot Medical ( (MBOT) ) has provided an update.
Microbot Medical said on May 14, 2026, that it successfully transitioned from limited to full commercial release of its LIBERTY Endovascular Robotic System, generating its first revenues in the quarter ended March 31, 2026 and already surpassing that level midway through the second quarter as account numbers more than doubled. Hospitals in six U.S. states, including multiple sites in Boston and two former pivotal trial centers, have adopted the system and used it across a broad range of complex embolization procedures, signaling early commercial traction, recurring orders and a growing pipeline that could strengthen the company’s position in the emerging endovascular robotics market.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is a first-of-its-kind single-use, remotely operated platform designed to improve precision, efficiency and safety in vascular interventions, targeting hospitals and interventional specialists in key U.S. markets.
Average Trading Volume: 1,699,508
Technical Sentiment Signal: Sell
Current Market Cap: $147.1M
See more data about MBOT stock on TipRanks’ Stock Analysis page.